ArticleBlood cancer journal2022

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.

Burcu Aslan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.